Anti-EGFR strategy for colorectal cancer: Searching for the real target

被引：0

作者：

Zaniboni, A. ^{[1
]}

Meriggi, F. ^{[1
]}

机构：

[1] Fdn Poliambulanza, UO Oncol Med, I-25100 Brescia, Italy

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2006年 / 3卷 / 08期

关键词：

cetuximalb; colorectal cancer; anti-EGFR therapy;

D O I：

10.2174/157018006778194673

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancer. Cetuximab is a recombinant human/mouse monoclonal antibody(MoAb) against EGFR, clinically active in the treatment of human colorectal cancer. Unlike the predictable correlation of response to trastuzumab, another MoAb clinically active in a subgroup of breast cancer patients expressing HER-2/neu, responses to cetuximab in EGFR-expressing colorectal cancer is not predictable.

引用

页码：541 / 543

页数：3

共 50 条

[21] EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer [J].

Birkman, Eva-Maria ;

Avoranta, Tuulia ;

Algars, Annika ;

Korkeila, Eija ;

Lintunen, Minnamaija ;

Lahtinen, Laura ;

Kuopio, Teijo ;

Ristamaki, Raija ;

Carpen, Olli ;

Sundstrom, Jari .

HUMAN PATHOLOGY, 2018, 82 :163-171

[22] Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer [J].

Masahiro Inoue ;

Shin Takahashi ;

Hiroshi Soeda ;

Hideki Shimodaira ;

Mika Watanabe ;

Koh Miura ;

Iwao Sasaki ;

Shunsuke Kato ;

Chikashi Ishioka .

International Journal of Clinical Oncology, 2015, 20 :1147-1155

[23] Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation [J].

Kishiki, Tomokazu ;

Ohnishi, Hiroaki ;

Masaki, Tadahiko ;

Ohtsuka, Kouki ;

Ohkura, Yasuo ;

Furuse, Jyunji ;

Sugiyama, Masanori ;

Watanabe, Takashi .

ONCOLOGY REPORTS, 2014, 32 (01) :57-64

[24] Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer [J].

Inoue, Masahiro ;

Takahashi, Shin ;

Soeda, Hiroshi ;

Shimodaira, Hideki ;

Watanabe, Mika ;

Miura, Koh ;

Sasaki, Iwao ;

Kato, Shunsuke ;

Ishioka, Chikashi .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (06) :1147-1155

[25] EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer [J].

A Ålgars ;

M Lintunen ;

O Carpén ;

R Ristamäki ;

J Sundström .

British Journal of Cancer, 2011, 105 :255-262

[26] EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer [J].

Algars, A. ;

Lintunen, M. ;

Carpen, O. ;

Ristamaki, R. ;

Sundstrom, J. .

BRITISH JOURNAL OF CANCER, 2011, 105 (02) :255-262

[27] Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer [J].

Zacharenia Saridaki ;

Vassilis Georgoulias ;

John Souglakos .

World Journal of Gastroenterology, 2010, 16 (10) :1177-1187

[28] Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients [J].

Santini, Daniele ;

Pantano, Francesco ;

Vincenzi, Bruno ;

Loupakis, Fotios ;

Caraglia, Michele ;

Falcone, Alfredo ;

Tonini, Giuseppe .

EJC SUPPLEMENTS, 2008, 6 (14) :86-90

[29] Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? [J].

Derangere, Valentin ;

Fumet, Jean David ;

Boidot, Romain ;

Bengrine, Leila ;

Limagne, Emeric ;

Chevriaux, Angelique ;

Vincent, Julie ;

Ladoire, Sylvain ;

Apetoh, Lionel ;

Rebe, Cedric ;

Ghiringhelli, Francois .

ONCOTARGET, 2016, 7 (08) :9310-9322

[30] Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era [J].

Eric Van Cutsem ;

Sabine Tejpar .

Targeted Oncology, 2008, 3 :223-225

← 1 2 3 4 5 →